qcrB Family assigned · medium auto-curated

H37Rv Rv2196 · MTBC0 mtbc0_002332 · 549 aa · 2485685–2487334 MTBC0 (+) · RefSeq NP_216712.1

Genomic neighbourhood (genome browser)

Open in full genome browser →

This gene (outlined) in its genomic context; arrows are neighbouring genes coloured by verdict. Click any gene to navigate. Pan and zoom in the full browser.

Annotation: from legacy to revised

Legacy (H37Rv / Mycobrowser)ubiquinol-cytochrome C reductase cytochrome subunit B
MTBC0 PGAP re-annotationcytochrome bc complex cytochrome b subunit
Revised (this work)Cytochrome bc complex cytochrome b subunit. Pfam: Cytochrome_B (PF00033.25), Cytochrom_B_N_2 (PF13631.12).
Functional category (TubercuList)intermediary metabolism and respiration

Auto-curated: this verdict and function were generated by rules from PGAP + Pfam + Foldseek and have not been hand-reviewed.

In the literature (TB corpus sweep) 72 publications

72 TB publications mention this gene. 72 publications discuss this gene. Queried separately, 70 records carry a M. tuberculosis context and 10 a non-TB mycobacterial context (species named in the 10-record verified sample: M. smegmatis (5), M. abscessus (4), M. marinum (1)). The three counts come from three distinct PubMed queries (each with its own context filter), so they neither partition the total nor need to add up to it.

5 of 72: the most recently indexed records of the curated sweep at its date, not necessarily the most recent papers on this gene — the exhaustive list below is later and broader and may hold newer ones.
PublicationDate
4‑Aminoalkylquinolines as Potent Antitubercular Agents Targeting the Cytochrome bc1 Complex. doi:10.1021/acsmedchemlett.6c00183 2026
Respiratory chain gene mutations associated with global phylogenetic clustering of drug-resistant Mycobacterium tuberculosis revealed by whole-genome sequencing. doi:10.3389/fimmu.2026.1724194 2026
QcrB inhibitor Q203 (Telacebec) can synergize with clofazimine and clarithromycin to control a Mycobacterium avium infection. doi:10.1371/journal.pone.0344608 2026
The Mycobacterium abscessus cytochrome bcc:aa3 oxidase structure paves the way for an agent targeting subunit QcrB. doi:10.1038/s41467-026-70805-5 2026
Halting Tuberculosis in Its Tracks: Advances and Strategies for Discovering Therapeutic Targets in Mycobacterium tuberculosis. doi:10.1002/ddr.70239 2026
73 records returned by the alias sweep (a separate sweep from the 72 above; both are shown, neither is exhaustive)

Searched as: Rv2196, qcrB, Mb2219, ML0879c, MMAR_3240, MSMEG_4263, MAB_1966c — each in conjunction with a mycobacterial context term. Swept 2026-09-07.

PublicationJournalYear
Dual inhibition of respiratory complexes in Mycobacterium tuberculosis results in bacterial killing. doi:10.1128/spectrum.00643-26 Microbiol Spectr 2026
4‑Aminoalkylquinolines as Potent Antitubercular Agents Targeting the Cytochrome bc(1) Complex. doi:10.1021/acsmedchemlett.6c00183 ACS Med Chem Lett 2026
Respiratory chain gene mutations associated with global phylogenetic clustering of drug-resistant Mycobacterium tuberculosis revealed by whole-genome sequencing. doi:10.3389/fimmu.2026.1724194 Front Immunol 2026
QcrB inhibitor Q203 (Telacebec) can synergize with clofazimine and clarithromycin to control a Mycobacterium avium infection. doi:10.1371/journal.pone.0344608 names it PLoS One 2026
The Mycobacterium abscessus cytochrome bcc:aa(3) oxidase structure paves the way for an agent targeting subunit QcrB. doi:10.1038/s41467-026-70805-5 names it Nat Commun 2026
Halting Tuberculosis in Its Tracks: Advances and Strategies for Discovering Therapeutic Targets in Mycobacterium tuberculosis. doi:10.1002/ddr.70239 Drug Dev Res 2026
Reference-based chemical-genetic interaction profiling to elucidate small molecule mechanism of action in Mycobacterium tuberculosis. doi:10.1038/s41467-025-64662-x Nat Commun 2025
Structure-Activity Relationship Study of Benzamides as Mycobacterium tuberculosis QcrB Inhibitors. doi:10.1021/acsmedchemlett.5c00252 names it ACS Med Chem Lett 2025
Synthesis of 1,3-diaryl substituted pyrazole-based imidazo[1,2-a]pyridine carboxamides and evaluation of their antitubercular activity. doi:10.1016/j.bmc.2025.118341 Bioorg Med Chem 2025
Scaffold Hopping Strategy toward New 4‑Aminoquinazolines Active Against Extracellular and Intracellular. doi:10.1021/acsmedchemlett.5c00276 ACS Med Chem Lett 2025
New Triazolopyrimidines with Improved Activity against Mycobacterium tuberculosis. doi:10.1021/acsmedchemlett.5c00073 ACS Med Chem Lett 2025
Contribution of telacebec to novel drug regimens in a murine tuberculosis model. doi:10.1128/aac.00962-24 Antimicrob Agents Chemother 2025
Association of mutations in Mycobacterium tuberculosis complex (MTBC) respiration chain genes with hyper-transmission. doi:10.1186/s12864-024-10726-z BMC Genomics 2024
Exploring Scaffold Hopping for Novel 2-(Quinolin-4-yloxy)acetamides with Enhanced Antimycobacterial Activity. doi:10.1021/acsmedchemlett.3c00570 ACS Med Chem Lett 2024
Benzene Amide Ether Scaffold is Active against Non-replicating and Intracellular Mycobacterium tuberculosis. doi:10.1021/acsinfecdis.3c00275 ACS Infect Dis 2023
Characterization of Two Novel Inhibitors of the Mycobacterium tuberculosis Cytochrome bc(1) Complex. doi:10.1128/aac.00251-23 Antimicrob Agents Chemother 2023
Synthesis and antitubercular activity of novel 4-arylalkyl substituted thio-, oxy- and sulfoxy-quinoline analogues targeting the cytochrome bc1 complex. doi:10.1016/j.bioorg.2023.106659 Bioorg Chem 2023
QcrB inhibition as a potential approach for the treatment of tuberculosis: A review of recent developments, patents, and future directions. doi:10.1016/j.jiph.2023.04.011 names it J Infect Public Health 2023
Targeting mycobacterial membranes and membrane proteins: Progress and limitations. doi:10.1016/j.bmc.2023.117212 Bioorg Med Chem 2023
Investigation of protein-ligand binding motions through protein conformational morphing and clustering of cytochrome bc1-aa3 super complex. doi:10.1016/j.jmgm.2022.108347 J Mol Graph Model 2023
Synergistic Effect of Q203 Combined with PBTZ169 against Mycobacterium tuberculosis. doi:10.1128/aac.00448-22 Antimicrob Agents Chemother 2022
Syntheses and studies of deuterated Imdiazo[1,2-a]pyridine-3-carboxamides with potent anti-tuberculosis activity and improved metabolic properties. doi:10.1016/j.bioorg.2022.106074 Bioorg Chem 2022
Antitubercular Activity of Novel 2-(Quinoline-4-yloxy)acetamides with Improved Drug-Like Properties. doi:10.1021/acsmedchemlett.2c00254 ACS Med Chem Lett 2022
Prediction of QcrB Inhibition as a Measure of Antitubercular Activity with Machine Learning Protocols. doi:10.1021/acsomega.2c01613 names it ACS Omega 2022
Chemical Exploration of a Highly Selective Scaffold with Activity against Intracellular Mycobacterium tuberculosis. doi:10.1128/spectrum.01161-22 Microbiol Spectr 2022
Triazolopyrimidines Target Aerobic Respiration in Mycobacterium tuberculosis. doi:10.1128/aac.02041-21 Antimicrob Agents Chemother 2022
Sensitivity of Mycobacterium leprae to Telacebec. doi:10.3201/eid2803.210394 Emerg Infect Dis 2022
Ursolic acid as a potential inhibitor of Mycobacterium tuberculosis cytochrome bc1 oxidase-a molecular modelling perspective. doi:10.1007/s00894-021-04993-w J Mol Model 2022
Utilization of CRISPR interference to investigate the contribution of genes to pathogenesis in a macrophage model of Mycobacterium tuberculosis infection. doi:10.1093/jac/dkab437 J Antimicrob Chemother 2022
Targeting the cytochrome bc(1) complex for drug development in M. tuberculosis: review. doi:10.1007/s11030-021-10335-y Mol Divers 2022
Cytochrome bc1-aa3 Oxidase Supercomplex As Emerging and Potential Drug Target Against Tuberculosis. doi:10.2174/1874467214666210928152512 Curr Mol Pharmacol 2022
Design, synthesis and SAR of antitubercular benzylpiperazine ureas. doi:10.1007/s11030-020-10158-3 Mol Divers 2022
Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon? doi:10.5817/CSF2021-5-164 Ceska Slov Farm 2021
Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon? doi:10.5817/CSF2021-5-164 Ceska Slov Farm 2021
Structure of Mycobacterium tuberculosis cytochrome bcc in complex with Q203 and TB47, two anti-TB drug candidates. doi:10.7554/eLife.69418 Elife 2021
In-silico design and ADMET predictions of some new imidazo[1,2-a]pyridine-3-carboxamides (IPAs) as anti-tubercular agents. doi:10.1016/j.jctube.2021.100276 J Clin Tuberc Other Mycobact Dis 2021
The QcrB Inhibitors TB47 and Telacebec Do Not Potentiate the Activity of Clofazimine in Mycobacterium abscessus. doi:10.1128/AAC.00964-21 names it Antimicrob Agents Chemother 2021
Sterilizing Effects of Novel Regimens Containing TB47, Clofazimine, and Linezolid in a Murine Model of Tuberculosis. doi:10.1128/AAC.00706-21 Antimicrob Agents Chemother 2021
3-Aryl-substituted imidazo[1,2-a]pyridines as antituberculosis agents. doi:10.1002/ardp.202000419 Arch Pharm (Weinheim) 2021
Structure guided generation of thieno[3,2-d]pyrimidin-4-amine Mycobacterium tuberculosis bd oxidase inhibitors. doi:10.1039/d0md00398k RSC Med Chem 2021
Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance for Mycobacterium ulcerans. doi:10.1016/j.apsb.2020.11.007 Acta Pharm Sin B 2021
Bipolar Distribution of Minimum Inhibitory Concentration of Q203 Across Mycobacterial Species. doi:10.1089/mdr.2020.0239 Microb Drug Resist 2021
Homology modeling and molecular docking simulation of some novel imidazo[1,2-a]pyridine-3-carboxamide (IPA) series as inhibitors of Mycobacterium tuberculosis. doi:10.1186/s43141-020-00102-1 J Genet Eng Biotechnol 2021
Small organic molecules targeting the energy metabolism of Mycobacterium tuberculosis. doi:10.1016/j.ejmech.2020.113139 Eur J Med Chem 2021
QcrB in Mycobacterium tuberculosis: The new drug target of antitubercular agents. doi:10.1002/med.21779 names it Med Res Rev 2021
Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis. doi:10.1021/acsinfecdis.0c00675 ACS Infect Dis 2021
TB47 and clofazimine form a highly synergistic sterilizing block in a second-line regimen for tuberculosis in mice. doi:10.1016/j.biopha.2020.110782 Biomed Pharmacother 2020
Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against M. tuberculosis Enzyme Targets. doi:10.2174/1568026620666200903163921 Curr Top Med Chem 2020
Design, synthesis, and evaluation of new 2-(quinoline-4-yloxy)acetamide-based antituberculosis agents. doi:10.1016/j.ejmech.2020.112179 Eur J Med Chem 2020
New 2-Ethylthio-4-methylaminoquinazoline derivatives inhibiting two subunits of cytochrome bc1 in Mycobacterium tuberculosis. doi:10.1371/journal.ppat.1008270 PLoS Pathog 2020
Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds. doi:10.1371/journal.pone.0227224 PLoS One 2020
Refined homology model of cytochrome bcc complex B subunit for virtual screening of potential anti-tuberculosis agents. doi:10.1080/07391102.2019.1688196 J Biomol Struct Dyn 2020
Naturally-Occurring Polymorphisms in QcrB Are Responsible for Resistance to Telacebec in Mycobacterium abscessus. doi:10.1021/acsinfecdis.9b00322 names it ACS Infect Dis 2019
Identification of 4-Amino-Thieno[2,3-d]Pyrimidines as QcrB Inhibitors in Mycobacterium tuberculosis. doi:10.1128/mSphere.00606-19 names it mSphere 2019
Novel MenA Inhibitors Are Bactericidal against Mycobacterium tuberculosis and Synergize with Electron Transport Chain Inhibitors. doi:10.1128/AAC.02661-18 Antimicrob Agents Chemother 2019
Pyrazolo[1,5- a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis. doi:10.1021/acsinfecdis.8b00225 ACS Infect Dis 2019
Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis. doi:10.1128/mBio.01276-18 names it mBio 2018
Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB. doi:10.1021/acs.jmedchem.8b00172 names it J Med Chem 2018
Imidazopyridine Compounds Inhibit Mycobacterial Growth by Depleting ATP Levels. doi:10.1128/AAC.02439-17 Antimicrob Agents Chemother 2018
Drug discovery in tuberculosis. New drug targets and antimycobacterial agents. doi:10.1016/j.ejmech.2018.03.020 Eur J Med Chem 2018
Mycobacterial Membrane Proteins QcrB and AtpE: Roles in Energetics, Antibiotic Targets, and Associated Mechanisms of Resistance. doi:10.1007/s00232-017-9997-3 names it J Membr Biol 2018
Combinations of Respiratory Chain Inhibitors Have Enhanced Bactericidal Activity against Mycobacterium tuberculosis. doi:10.1128/AAC.01677-17 Antimicrob Agents Chemother 2018
Activity of 2-(quinolin-4-yloxy)acetamides in Mycobacterium tuberculosis clinical isolates and identification of their molecular target by whole-genome sequencing. doi:10.1016/j.ijantimicag.2017.08.023 Int J Antimicrob Agents 2018
Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies. doi:10.1021/acs.jmedchem.7b01347 J Med Chem 2017
Improved Phenoxyalkylbenzimidazoles with Activity against Mycobacterium tuberculosis Appear to Target QcrB. doi:10.1021/acsinfecdis.7b00112 names it ACS Infect Dis 2017
Arrival of Imidazo[2,1-b]thiazole-5-carboxamides: Potent Anti-tuberculosis Agents That Target QcrB. doi:10.1021/acsinfecdis.5b00154 names it ACS Infect Dis 2016
SAR and identification of 2-(quinolin-4-yloxy)acetamides as Mycobacterium tuberculosis cytochrome bc(1) inhibitors. doi:10.1039/c6md00236f Medchemcomm 2016
Pyrrolo[3,4-c]pyridine-1,3(2H)-diones: A Novel Antimycobacterial Class Targeting Mycobacterial Respiration. doi:10.1021/acs.jmedchem.5b01542 J Med Chem 2015
Respiratory flexibility in response to inhibition of cytochrome C oxidase in Mycobacterium tuberculosis. doi:10.1128/AAC.03486-14 Antimicrob Agents Chemother 2014
Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? doi:10.1016/j.tube.2013.09.003 Tuberculosis (Edinb) 2013
Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB. doi:10.1371/journal.pone.0052951 names it PLoS One 2012
QcrCAB operon of a nocardia-form actinomycete Rhodococcus rhodochrous encodes cytochrome reductase complex with diheme cytochrome cc subunit. doi:10.1016/s0005-2728(02)00394-8 Biochim Biophys Acta 2003
A novel hydrophobic diheme c-type cytochrome. Purification from Corynebacterium glutamicum and analysis of the QcrCBA operon encoding three subunit proteins of a putative cytochrome reductase complex. doi:10.1016/s0005-2728(00)00205-x Biochim Biophys Acta 2001

Title+abstract index only: a paper that names this gene solely in its body text, a figure legend or a supplement is invisible here. That is why this list sits beside the curated layer rather than replacing it - Rv0007's characterisation, found by a full-text sweep, returns zero in this one. Absence from this list is not absence from the literature. Source: PubMed E-utilities sweep (esearch + esummary), every alias of the gene searched in conjunction with a mycobacterial context term; ambiguous common-word aliases excluded. phase198, 2026-09-06.

This layer CITES the literature and adds context; it does not change the verdict or the function stated elsewhere in this fiche. This distinguishes a gene that is dark because nobody has looked from one that is dark despite having been studied. Source: PubMed (whole): H37Rv locus tag + GENE NAME + ortholog identifiers (Mb…, MMAR_…, MSMEG_…, ML…, MAB_…), under a mycobacterial context filter; hits verified against the abstract text. Species-context counts distinguish M. tuberculosis literature from literature on other mycobacteria. phase76/phase77, 2026-07-13.

Genomic-neighbour overlap (structural caveat) co-directional · 0 % of gene

NeighbourqcrA (Rv2195, + strand)
Overlap4 bp, 0 % of this gene's length

co-directional overlap: ordinary (e.g. shared stop/start codons in an operon), not the Rv2438A-type artefact P20.1, derived from GFF3 gene coordinates, 2026-08-03.

CRISPRi vulnerability

Vulnerability index -7.75 (95% CI -8.30 to -7.17). A more negative index = more vulnerable to knockdown (better drug-target quality); indicative threshold VI ≤ -6 = highly vulnerable.

Quantitative CRISPRi knockdown, graded (finer than binary Tn-seq essentiality). Source: CRISPRi vulnerability index (Bosch 2021, supplementary Table S2 'mmc3.xlsx', bulk import via Europe PMC -- supersedes the per-gene pebble.rockefeller.edu scrape of phase46_crispri_vulnerability.py).

Legacy record & comparison (Mycobrowser)

Mycobrowser functionRespiration

The legacy Mycobrowser record is shown for verification. Mycobrowser is no longer maintained; its EC numbers predate recent nomenclature revisions, so a class change usually reflects re-numbering, not a conflict.

Orthologues (reciprocal best hits across mycobacteria)

M. bovis Mb2219 · 100.0% identity
M. leprae ML0879c · 92.5% identity
M. marinum MMAR_3240 · 88.9% identity
M. smegmatis MSMEG_4263 · 82.2% identity
M. orygis RJtmp_002267 · 99.8% identity
M. abscessus MAB_1966c · 78.3% identity

Reciprocal-best-hit orthologues (DIAMOND) against the Mycobrowser reference proteomes. A missing species is informative: e.g. a gene absent from M. leprae was likely lost in its reductive genome evolution. Locus tags link to Mycobrowser.

Curated reference (UniProt)

UniProt P9WP37 SwissProt · reviewed · Evidence at protein level
UniProt nameCytochrome bc1 complex cytochrome b subunit
EC (curated) EC 7.1.1.8
Curated functionCytochrome b subunit of the cytochrome bc1 complex, an essential component of the respiratory electron transport chain required for ATP synthesis. The bc1 complex catalyzes the oxidation of ubiquinol and the reduction of cytochrome c in the respiratory chain. The bc1 complex operates through a Q-cycle mechanism that couples electron transfer to generation of the proton gradient that drives ATP synthesis. The cytochrome b subunit contains two ubiquinol reactive sites: the oxidation (QP) site and the reduction (QN) site.

Functional vocabulary (eggNOG-mapper, orthology transfer)

COG category C Energy production and conversion
Preferred nameqcrB
eggNOG descriptionCytochrome b
Orthologous groupCOG1290
KEGG orthology K03891
KEGG pathways map00190, map01100
KEGG modules M00151
Gene Ontology (14) GO:0005575, GO:0005623, GO:0005886, GO:0005887, GO:0008150, GO:0016020, GO:0016021, GO:0031224, GO:0031226, GO:0040007, GO:0044425, GO:0044459 +2 more

Orthology-based transfer (eggNOG 5.0.2, diamond). EC/KO/GO/CAZy are computed annotations, not manual curation; cross-check against the primary literature before treating a specific reaction as established.

Conservation & selection (intra-MTBC, 142 601 strains, snapshot of 2026-09-29)

pN/pS 1.002 · relaxed/neutral
Polymorphic sites (≥ 0.1% of strains) 2 synonymous, 6 missense, 0 nonsense, 0 frameshift

pN/pS from segregating SNPs (singletons removed) normalised by possible sites. Low pN/pS = purifying selection (a strong signal that a "hypothetical" is a real, constrained gene). A high pN/pS is ambiguous: relaxed constraint or positive selection (drug resistance, antigenic variation) inflate it; e.g. rpoB/katG/pncA score high here for resistance, not loss of function. A clonal disruption (one allele over a clade) suggests lineage pseudogenisation; a convergent one (many independent alleles) is typical of resistance loss-of-function.

Outgroup conservation (beyond the MTBC) Actinomycetia

M. canettii dN/dS (deep-divergence selection) 0.0 (low power) · 1 consensus substitution(s)
low power (1 canettii-consensus substitution(s)); present in M. canettii but dN/dS not reliable
Limitation: dN/dS mixes fixed canettii-H37Rv divergence with intra-canettii polymorphism, and is not polarised (the per-gene repolarisation is not viable: 79 % of the consensus SPDI lie outside the polarised table).
Genus-wide presence (~53 non-MTBC Mycobacterium) present in 53/53 (100%) · mean identity 89.3% · 4/4 closest MTBAP relatives
conserved across the genus (present in 53/53 non-MTBC Mycobacterium genomes, incl. distant relatives) — an ancient core gene predating the genus radiation
Phylostratum (deepest detected homolog) MTBC-specific → Mycobacterium → Mycobacteriaceae → Corynebacteriales → Actinomycetia → Bacteria
detected in 10/13 non-Mycobacterium reference genomes (down to Actinomycetia) · mean identity 65.3%
detected across the class Actinomycetia (beyond Corynebacteriales) but not outside the phylum — an Actinobacteria-level ancient gene

Two orthogonal outgroup signals. M. canettii (the immediate outgroup) gives a deep-divergence dN/dS (a low value confirms a constrained, real gene; shown as confident only at ≥8 substitutions, else flagged low-power). Genus-wide presence/absence (tblastn vs assembled non-MTBC genomes) places the gene on the ancient-core ↔ MTBC-specific axis: a gene absent even from the closest MTBAP relatives is a candidate MTBC-specific innovation (possible host-adaptation factor, to confirm by synteny). The phylostratum extends that axis outside the genus (tblastn vs 13 reference genomes spanning Mycobacteriaceae → Corynebacteriales → Actinomycetia → outside the phylum): it is the deepest clade in which a homolog is still detected, i.e. a proxy for gene age. Read it with the null model in mind: a shallow (young) stratum can also reflect homology-detection failure for short or fast-evolving ORFs, so it is a descriptive axis, not a proof of novelty.

Essentiality (transposon mutagenesis) GD — not strictly essential

The two screens disagree on this gene: Tn-seq says growth-defect (insertions tolerated, NOT essential) (GD), CRISPRi says essential.

Two genome-wide screens disagree on this gene, and both are kept as they stand. They do not measure the same thing: the Tn-seq call (DeJesus 2017) reports tolerance to transposon insertion across the ORF, the CRISPRi call (Bosch 2021) reports tolerance to partial knockdown. A gene can absorb an insertion and still be required at full dosage, or the reverse. Here the CRISPRi estimate is a confident one (its `certain` flag is set, vulnerability index -7.745), so the disagreement is a genuine methodological tension rather than a weak fit. Atlas-wide, 89 gene(s) fall in this exact stratum, out of 193 showing this direction of disagreement.

DeJesus 2017 callGD · growth-defect
What the call meansgrowth-defect: insertions tolerated but fitness reduced; NOT essential
TA sites (Himar1) 31 in the ORF — 0 in the essential state, 28 growth-defect, 3 non-essential, 0 growth-advantage. Saturation 0.419, mean read count 12.3846153846. A region of the protein devoid of TA sites is invisible to this assay: nothing can be inferred about it, in either direction.
All 31 sites lie in this ORF alone (no overlapping CDS shares any), so the call is attributable to this gene.
Caveat`essential: true` here is the broad union (ES+ESD+GD) kept for backward compatibility; this gene is NOT strictly essential. Read n_sites_* before writing anything about essentiality.

Genome-wide Himar1 transposon essentiality in H37Rv (DeJesus 2017). An essential call (ES/ESD/GD) is strong, independent evidence that a "hypothetical" locus encodes a functional, selectively required gene — orthogonal to intra-species conservation.

Chemical-genetic target & druggability (PROSPECT) hypomorph tool strain validated drug target

This gene is part of the PROSPECT collection of TetON transcriptional-knockdown (hypomorph) strains of essential M. tuberculosis genes, built as a sensitised background for chemical-genetic mechanism-of-action deconvolution. Being in the panel means the gene is an essential / vulnerable target for which a validated knockdown tool strain exists.

Hypomorph strainRv2196-qcrB_teton1.1 (TetON promoter 1)
Baseline knockdown fitness2.318 median doublings (across 6 screen pool(s)) — fewer doublings = stronger growth defect on knockdown
Used in target deconvolutionyes (informs phenotypic-cluster / MOA assignment)
Drug-target cross-referenceannotated mechanism-of-action target QcrB: 7 reference compound(s) phenocopy its inhibition — chemically-validated druggable target

Panel membership reflects essentiality/vulnerability and the availability of a genetic tool, not a specific molecular function; it never changes the verdict here. Source: Bond AN et al., Nat Commun 2025;16:9673 (doi:10.1038/s41467-025-64662-x); PROSPECT chemical-genetic platform.

Proteomics (mass spectrometry) detected

MS detectiondetected in 12 of 16 independent MS datasets
Integrated abundance315.0 ppm · rank 621/3519 (82.4th percentile)

Detection by mass spectrometry is direct, experimental evidence that the protein product exists — orthogonal to sequence conservation and to Tn-seq essentiality, and especially decisive for a "hypothetical" locus. Read the dataset count as abundance, not as replication. Measured across this atlas (3,491 detected proteins), the number of datasets a protein appears in tracks its abundance almost monotonically: median 1.2 ppm at 1 dataset of 16, 27 ppm at 10, 392 ppm at 15, 1,325 ppm at 16 — three orders of magnitude. A high count therefore says the protein is abundant more than it says several independent experiments confirmed it. What the count does establish, at any value, is that the product exists.

Predicted localisation (DeepTMHMM + lipobox)

Predictionpredicted membrane protein (8 TM helixes)
DeepTMHMM classTM
TM helices (DeepTMHMM)8

Transmembrane topology and signal peptide from DeepTMHMM (deep-learning reference predictor); lipoproteins from a (myco)bacterial lipobox motif. A sequence-based prediction of subcellular context.

Physico-chemical properties (computed, ProtParam)

Length549 aa
Molecular weight61.0 kDa
Theoretical pI8.49
GRAVY0.324 (hydrophobic)
Aliphatic index105.4
Aromaticity0.12
Instability index45.1 (unstable)

Computed from the ancestral MTBC0 sequence with the ExPASy ProtParam method (Biopython). Descriptive biophysical context: a positive GRAVY flags a hydrophobic (often membrane) protein, a high instability index (>40) predicts a short in-vitro half-life, an extreme pI hints at compartment or binding partner.

Domains (Pfam, hmmscan --cut_ga)

PfamAccessioni-EvalueResiduesDescription
Cytochrome_BPF00033.25 3.9e-2345–235 Cytochrome b/b6/petB
Cytochrom_B_N_2PF13631.12 1.1e-64120–294 Cytochrome b(N-terminal)/b6/petB

3D structure (interactive — Mol*/pdbe-molstar)

Experimental structure 7e1w (PDBe), the strongest available structural evidence for this gene. Drag to rotate, scroll to zoom; hetero-groups (ligands, ions, waters hidden by default) shown as sticks.

Experimental structures (Protein Data Bank) 4 solved

PDBMethodResolutionCoverage
7e1w Electron Microscopy 2.67 Å 100%
7e1v Electron Microscopy 2.68 Å 100%
7e1x Electron Microscopy 2.93 Å 100%
8hcr Electron Microscopy 4.5 Å 100%

Experimentally solved structures mapped from the UniProt accession via PDBe/SIFTS (4 total; up to 8 shown, ranked by sequence coverage then resolution). An experimental structure is direct proof of the folded product and the strongest structural evidence — superseding the predicted ESMFold/AlphaFold models below for any covered region.

Structural search (AlphaFold DB model, Foldseek vs PDB — genome-wide) pLDDT 94.8

PDB hitprobTM (aln)TM (query)TM (target)Seq. id.Cov. q / tE-valueDescription
7e1v-assembly1_N 1.00 0.99 0.94 0.99 100% 95% / 100% 3.1e-68 sig 7e1v-assembly1_N Cryo-EM structure of apo hybrid respiratory supercomplex consisting of Mycobacterium tuberculosis complexIII and Mycobacterium smegmatis complexIV
6hwh-assembly1_b 1.00 0.99 0.97 0.99 83% 97% / 100% 1.6e-61 sig 6hwh-assembly1_b Structure of a functional obligate respiratory supercomplex from Mycobacterium smegmatis
7qho-assembly1_O 1.00 0.98 0.95 0.98 62% 96% / 99% 1.1e-56 sig 7qho-assembly1_O Cytochrome bcc-aa3 supercomplex (respiratory supercomplex III2/IV2) from Corynebacterium glutamicum (as isolated)
9fu0-assembly1_H 1.00 0.99 0.78 0.99 84% 79% / 100% 4.3e-53 sig 9fu0-assembly1_H CIII2/CIV respiratory chain supercomplex from Mycobacterium smegmatis
7jrg-assembly1_C 1.00 0.78 0.57 0.78 20% 80% / 97% 5.2e-15 sig 7jrg-assembly1_C Plant Mitochondrial complex III2 from Vigna radiata

Foldseek search of the AlphaFold DB model (mean pLDDT 94.8, gated at 70) against the PDB — a genome-wide extension of the ESMFold dark-gene search that also covers proteins beyond the single-sequence length limit. Confident structural neighbours (E < 0.01) shown.

Genomic context (neighbours & predicted operon) operon of 4

Upstream (5' on genome)qcrA (+ strand, -4 bp gap)
Downstream (3' on genome)Rv2197c (- strand, 176 bp gap)
Predicted operon ctaE · qcrC · qcrA · qcrB

Neighbours from the H37Rv annotation (+ strand). The operon is predicted by co-directional intergenic distance (same strand, gaps ≤50 bp) — a transcription-unit hypothesis, not a mapped TSS. For a "hypothetical", co-transcription with a characterised operon is a concrete functional lead (complements the STRING neighborhood channel below).

Published operon evidence (two independent sources)

Roback 2007 (logistic regression: distance + expression correlation, 474 microarrays) operon of 4: ctaE · qcrC · qcrA · qcrB — agrees with the distance heuristic above
REMap 2016 (RNA-seq coverage continuity, CDC1551, tag MT2252) exponential phase: operon of 4, Rv2193 · Rv2194 · Rv2195 · Rv2196 (coverage 337.33)
stationary phase: operon of 4, Rv2193 · Rv2194 · Rv2195 · Rv2196 (coverage 67.17) — agrees with the distance heuristic above

Two independent published operon maps, cited alongside the distance heuristic above: an association corroborating or contradicting the heuristic, never proof of shared function. REMap's RNA-seq coverage continuity is the most direct of the three signals; Roback's logistic regression and the intergenic-distance heuristic are statistical proxies.

Transcriptional regulation (signed TRN: ChIP-seq + TFOE)

Regulated by (2 TF) Rv0081 (represses) · Rv0135c (activates)

Regulatory edges from the ISB signed transcriptional regulatory network (TF ChIP-seq binding, Minch 2015 + TF-overexpression response, Rustad 2014). An edge is regulatory evidence (binding and/or expression change), not necessarily direct. For a "hypothetical", membership in a known regulon (e.g. DosR dormancy, PhoP virulence) is a physiological-context lead, not a function.

Condition: Condition-blind by construction. These edges come from transcription-factor OVEREXPRESSION in a single laboratory condition, so a listed regulator is not a claim that it governs this gene in every circumstance. Measured counter-examples exist within this atlas (see Rv2516c, where the DosR regulon collapses under moxifloxacin while the gene itself rises). Read a regulator as 'capable of shifting this gene', and look for the condition before building a hypothesis on it.

Functional interaction network (STRING v12, guilt-by-association)

Explore full network →

Node colour = verdict, dashed = still uncharacterised; edge colour = evidence (green experimental, orange genomic-context, grey co-expression), width ∝ score. Click a partner to open its page; "Explore full network" to walk the graph.

Closest characterised functional partner: ctaE (cytochrome C oxidase subunit III), high confidence (score 1000, all STRING channels except text-mining; the partner is chosen on its genomic-context evidence). The pair's experimental or database support is transferred from orthologous pairs in other proteomes only: nothing was measured in M. tuberculosis, so it is an association inferred by orthology rather than measured in this organism.

Showing the 15 strongest of this gene's 161 partners at medium confidence (60 at high confidence). The table is an extract, not a neighbourhood: across the proteome the real median degree is 34 while the served median is 15, so no hub, degree distribution or centrality may be read on this table. None of the 161 partners rests on an interaction measured in M. tuberculosis itself.

PartnerProductScoreNo text-miningChannels (≥400)
Rv2193 ctaE exp (transferred) cytochrome C oxidase subunit III 999 1000 ctx neighborhood:822 cooccurence:699 coexpression:958 experimental:999 textmining:831
Rv2194 qcrC exp (transferred) curated ubiquinol-cytochrome C reductase cytochrome subunit C 999 1000 ctx neighborhood:881 cooccurence:773 coexpression:816 experimental:999 database:900 textmining:933
Rv2199c ctaF exp (transferred) cytochrome c oxidase polypeptide 4 999 1000 ctx cooccurence:768 coexpression:533 experimental:999 textmining:490
Rv2195 qcrA exp (transferred) curated ubiquinol-cytochrome C reductase rieske iron-sulfur subunit 999 1000 ctx neighborhood:881 cooccurence:772 coexpression:983 experimental:999 database:984 textmining:909
Rv3043c ctaD exp (transferred) cytochrome C oxidase cytochrome 1 999 1000 ctx cooccurence:604 coexpression:858 experimental:999 textmining:762
Rv2200c ctaC exp (transferred) cytochrome C oxidase subunit II 999 1000 ctx cooccurence:718 coexpression:857 experimental:999 textmining:846
Rv2876 exp (transferred) transmembrane protein 999 999 experimental:999
Rv0432 sodC exp (transferred) superoxide dismutase 997 997 experimental:997
Rv2782c pepR exp (transferred) curated zinc protease 989 989 experimental:928 database:844
Rv0863 exp (transferred) hypothetical protein 987 987 experimental:987
Rv3157 nuoM exp (transferred) NADH-quinone oxidoreductase subunit M 988 984 coexpression:840 experimental:902
Rv3152 nuoH exp (transferred) NADH-quinone oxidoreductase subunit H 987 984 coexpression:855 experimental:894
Rv3153 nuoI exp (transferred) NADH-quinone oxidoreductase subunit I 974 967 coexpression:655 experimental:903
Rv1304 atpB ATP synthase subunit A 972 964 coexpression:964
Rv3158 nuoN exp (transferred) NADH-quinone oxidoreductase subunit N 968 959 coexpression:654 experimental:886

STRING combines evidence channels (neighborhood, fusion, cooccurrence, coexpression, experimental, database, text-mining) into a 0–1000 score. The ctx badge marks edges carried by the genomic-context channels (conserved neighborhood, fusion, phylogenetic co-occurrence), which are independent of orthology and structure and the strongest signal for an unknown gene. The no text-mining column recomputes the score from data alone, so a link that does not depend on the literature is visible. Association is a function hypothesis, not proof: corroborate with the operon context and the primary literature before assigning a function.

Where the experimental evidence comes from, and why it matters here. STRING's experimental channel fuses interactions measured in M. tuberculosis with interactions measured in another organism and transferred to this pair by orthology. The two are not equivalent for this atlas, whose standing rule is that better studied elsewhere is not a function established in M. tuberculosis. Measured on the served network: of the 38 229 partner pairs shown across the atlas, 13 483 partner rows carry a non-zero experimental channel, and only 106 pairs rest on an interaction measured in M. tuberculosis itself — 0.3 % of the network. Those 106 are long-established complexes (ESX-1/ESAT-6, RNA polymerase with CarD and RbpA, the Pup–Mpa proteasome, gyrase, Emb, GarA with PknB and PknG, the Rel modules); no still-uncharacterised gene is among them. The reason is not a gap in this atlas but in the literature: there is almost no experimental interactome of this bacterium, IntAct holding 134 curated protein pairs for a ~4 000-gene proteome. A exp (transferred) badge is therefore a lead, never a measurement, and an absence of badge is not evidence that the pair does not interact.

Evidence

  • Legacy H37Rv annotation: ubiquinol-cytochrome C reductase cytochrome subunit B
  • MTBC0 PGAP product: cytochrome bc complex cytochrome b subunit
  • Pfam (hmmscan --cut_ga): Cytochrome_B PF00033.25 (E=4e-23), Cytochrom_B_N_2 PF13631.12 (E=1e-64)
  • (auto-curated by rules from PGAP + Pfam + Foldseek; not hand-reviewed)

Sources

  • Ancestral sequence & coordinates: Harrison LB et al. (2024), An imputed ancestral reference genome for the MTBC, doi:10.1101/2023.09.07.556366
  • Product annotation: NCBI PGAP on MTBC0; legacy from H37Rv NC_000962.3 (RefSeq NP_216712.1)
  • Domains: Pfam-A via hmmscan --cut_ga — Cytochrome_B (PF00033.25), Cytochrom_B_N_2 (PF13631.12)
  • Sequence-level signal: ESM Atlas (EvolutionaryScale × BioHub) — exploratory
  • Controlled vocabulary: eggNOG-mapper 2.1.12 (Cantalapiedra et al. 2021, doi:10.1093/molbev/msab293), eggNOG 5.0 DB (Huerta-Cepas et al. 2019) — OG COG1290
  • Curated reference: UniProt P9WP37 (SwissProt, reviewed; Evidence at protein level)
  • Intra-MTBC selection: pN/pS and disruption from SPDI variants of 142 601 MTBC strains (this work, local collection vs H37Rv NC_000962.3)
  • Genome-wide structure: AlphaFold DB model (Jumper et al. 2021, doi:10.1038/s41586-021-03819-2; Varadi et al. 2024, doi:10.1093/nar/gkad1011) searched vs PDB with Foldseek (mean pLDDT 94.8)
  • Interaction network: STRING v12.0 (Szklarczyk et al. 2023, doi:10.1093/nar/gkac1000), taxon 83332, CC-BY 4.0 — 161 functional partner(s); context anchor ctaE
  • Essentiality: genome-wide transposon mutagenesis in H37Rv — DeJesus et al. 2017 (mBio, doi:10.1128/mBio.02133-16, CC BY)
  • Proteomics: integrated mass-spectrometry abundance from PaxDb 5.0 (Huang et al. 2023, doi:10.1016/j.mcpro.2023.100640), taxon 83332 — weighted average of 16 datasets, incl. Schubert et al. 2013 (doi:10.1016/j.chom.2013.04.008) and Albrethsen et al. 2013 (doi:10.1074/mcp.M112.018846)
  • Functional category: TubercuList scheme (Cole et al. 1998, doi:10.1038/31159), via Mycobrowser (Kapopoulou et al. 2011, doi:10.1016/j.tube.2010.09.006)
  • Orthologues: reciprocal best hits (DIAMOND, Buchfink et al. 2021, doi:10.1038/s41592-021-01101-x) against Mycobrowser release 5 reference proteomes
  • Experimental structures: PDBe/SIFTS UniProt→PDB mapping (Dana et al. 2019, doi:10.1093/nar/gky1114)
  • Genomic context / operon: H37Rv annotation; operon predicted by co-directional intergenic distance (Salgado et al. 2000, doi:10.1073/pnas.030539397)
  • Transcriptional regulation: ISB signed TRN — TF ChIP-seq (Minch et al. 2015, doi:10.1038/ncomms6829) + TF overexpression (Rustad et al. 2014, doi:10.1186/gb-2014-15-11-502)
  • Physico-chemical properties: ExPASy ProtParam method via Biopython (Gasteiger et al. 2005), computed from the MTBC0 sequence
  • Predicted localisation: DeepTMHMM (Hallgren et al. 2022, doi:10.1101/2022.04.08.487609) for transmembrane topology and signal peptide
  • Primary literature: none located yet; annotation rests on the domain/homology sources above.

Ancestral MTBC0 protein sequence

>mtbc0_002332|Rv2196|qcrB
MSPKLSPPNIGEVLARQAEDIDTRYHPSAALRRQLNKVFPTHWSFLLGEIALYSFVVLLITGVYLTLFFDPSMVDVTYNGVYQPLRGVEMSRAYQSALDISFEVRGGLFVRQIHHWAALMFAAAIMVHLARIFFTGAFRRPRETNWVIGSLLLILAMFEGYFGYSLPDDLLSGLGLRAALSSITLGMPVIGTWLHWALFGGDFPGTILIPRLYALHILLLPGIILALIGLHLALVWFQKHTQFPGPGRTEHNVVGVRVMPVFAFKSGAFFAAIVGVLGLMGGLLQINPIWNLGPYKPSQVSAGSQPDFYMMWTEGLARIWPPWEFYFWHHTIPAPVWVAVIMGLVFVLLPAYPFLEKRFTGDYAHHNLLQRPRDVPVRTAIGAMAIAFYMVLTLAAMNDIIALKFHISLNATTWIGRIGMVILPPFVYFITYRWCIGLQRSDRSVLEHGVETGIIKRLPHGAYIELHQPLGPVDEHGHPIPLQYQGAPLPKRMNKLGSAGSPGSGSFLFADSAAEDAALREAGHAAEQRALAALREHQDSIMGSPDGEH